Lonicera japonica‐Derived Nanovesicles Ameliorate Acute Lung Injury by Suppressing Neutrophil Extracellular Traps Formation in Mice Authors: Xi Lin, Jian Lin, Yezi Zhang, Xinyan Zhang, Xinghua Liu, Hongying Cao, Huan Shen, Jianming Liang, Zhenhua Dai, Siyuan Xu, Xingdong Lin Published: 2026 ABSTRACT ABSTRACTAcute lung injury (ALI) is a lethal respiratory disease. The inflammatory storm triggered by neutrophil extracellular traps (NETs) is the critical pathogenesis of pulmonary injury. But the effective clinical treatments remain limited for ALI. Hence, developing a pulmonary‐targeting nano‐drug is urgent in the clinic. Lonicera japonica‐derived nanovesicles (LDNVs) was isolated and characterized. Distribution of LDNVs were enriched in the pulmonary neutrophils. LDNVs restored the body weight, physical activity and attenuated the pulmonary injury of LPS‐induced ALI mice. The inflammatory cytokines and neutrophil‐associated chemokines were decreased with LDNVs treatment. LDNVs also decreased pulmonary accumulation of neutrophils and NETs. The LC3B II was suppressed and p62 was enhanced by LDNVs treatment. Finally, LDNVs suppressed the translocation of LC3 in nuclear and lysosomal damage. But these therapeutic effects of LDNVs in ALI and NETs were both blocked by a neutrophils and NETs activator, phorbol myristate acetate (PMA). LDNVs attenuate LPS‐induced ALI by inhibiting NETs formation. These effects may be associated with LDNVs suppressing the autophagic flux.Keywords: acute lung injury, Lonicera japonica‐derived nanovesicles, neutrophil extracellular traps and autophagic flux, pulmonary targeting Abbreviations acute lung injury alanine aminotransferase alpha smooth muscle actin aspartate aminotransferase blood urea nitrogen bronchoalveolar lavage fluid citrullinated histone H3 creatinine dexamethasone exosome fluorescent labeling dye hematoxylin and eosin lipopolysaccharide Lonicera japonica extract Lonicera japonica‐derived nanovesicles mean fluorescence intensity myeloperoxidase neutrophil extracellular traps optical Density phorbol myristate acetate polydispersity thin‐layer chromatography transmission electron microscopy Introduction Acute lung injury (ALI) is a severe respiratory disease. Despite the clinical supportive techniques improving in the last decades, the hospital mortality of ALI is still more than 40% because of limited effective drugs [1]. Acute infection is the most common etiology of ALI. Especially the pandemic of COVID‐19 induced ALI caused mass mortality worldwide [2]. Bacteria‐ and virus‐elicited immune responses are the direct pathogenesis of inflammatory pulmonary injury [3], which leads to alveolar damage, pulmonary edema, and respiratory failure [4]. Neutrophils are the first cells to be recruited against infection [5]. Neutrophils host and clear pathogens by forming neutrophil extracellular traps (NETs) and producing antibacterial peptides, reactive oxygen species, and inflammatory cytokines [6, 7]. However, excessive activation of neutrophils and NETs formation are identified as key features of lung injury [5]. In the pandemic of COVID‐19, overactivation of neutrophils and NETs was considered a predictor of risk for worse outcomes [7]. Hence, balancing the immune activity of the neutrophils and NETs formation is an effective strategy for treating ALI. Autophagy is a highly conserved cellular process for cytoplasmic constituents’ recirculation and degradation. A double membrane‐formed autophagosome captures the cargo and fuses it into a lysosome for recycling and degradation [8]. Considering the infection is the classic cause of cell stress, autophagy is a frequent process in immune cells during infection [9]. Under infection, autophagy is activated in neutrophils to phagocytose pathogens and harmful redundancy and to degrade damaged cellular fragments [10]. However, excess autophagic flux will break the stability of lysosomes and promote death of neutrophils and NETosis [10, 11]. Therefore, exploring a lung targeted nano‐drug to suppress autophagy and NETosis is attractive for ALI treatment. The pulmonary endothelial system is tightly connected and restricts drug passage and distribution [12]. Hence, the size of nanoparticles is critical for lung targeting. The pulmonary capillary network possesses a 100–140 m2 interface for gas exchange, which also permits particles to cross [12, 13]. Meanwhile, the inflammatory microenvironment under ALI also breaks the pulmonary capillary barrier and facilitates the permeation of nanoparticles. On the other hand, the clearance of nanoparticles by alveolar macrophages depends on the size (100–1000 nm) [14]. Otherwise, nanoparticles smaller than 40 nm easily translocate from the lungs to lymph nodes and the blood circulation [14]. These findings indicate that nanoparticles with sizes ranging from 40 to 100 nm tend to distribute in the lungs. Plant‐derived nanoparticles (PDNVs) have displayed potential therapeutic effects and drug delivery abilities in last decade [15]. These nanoparticles have good biocompatibility, low immunogenicity, and high bio‐safety [15]. Meanwhile, PDNVs possess protein, lipid, nucleic acid, and other pharmacologically active components, which exhibit immunological regulating, anti‐tumor, and anti‐inflammation effects [16]. In previous researches, Lonicera japonica extract displayed potential therapeutic effects in ALI mice [17, 18]. But the specific mechanism and appropriate pharmaceutical preparation are still pressing. Hence, the Lonicera japonica‐derived nanovesicles (LDNVs) were isolated and explored for lung targeting and therapeutic mechanisms in lipopolysaccharide (LPS)‐induced ALI mice. Materials and Methods Isolation of LDNVs Dried Lonicera japonica were purchased from Fengliaoxing Pharmaceuticals (Guangdong, China). The mixture was prepared in the ratio of 1:5 of Lonicera japonica and PBS. The herb was pulverized with PBS for 5 min, then filtered through gauze and centrifuged. Debris was removed by continuous differential centrifugation (2000 g centrifugation for 20 min, 3000 g centrifugation for 30 min, and 12 000 g centrifugation for 60 min). The supernatant was collected and ultra‐centrifuged at 150 000 g for 90 min. The centrifuged precipitate was resuspended in PBS. The solution was filtered through a 1, 0.45, and 0.22 µm filter membrane and ultrafiltered by ultrafiltration tubes to collect the purified LDNVs for immediate use or storage at 4°C. Nanoparticle Tracking Analysis and Zeta Potential Analysis The purified LDNVs solution was analyzed using a Flow NanoAnalyzer to determine particle size and concentration. The zeta potential and polydispersity (PDI) were analyzed by Particle Size and Zeta Potential Analyzer. Transmission Electron Microscope Observation The obtained LDNVs solution was dropped onto a copper mesh with a supporting film. After resting still for 10 min, the copper mesh was removed, and the remaining water droplets were absorbed. 10 µL of 2% uranyl acetate solution was pipetted onto the surface of the copper mesh and left to stand for 2 min before the excess solution was aspirated. The copper mesh was dried naturally for 10 min, and the microstructure of the sample was observed by transmission electron microscopy (TEM) under 100 kV acceleration voltage. Gel Electrophoresis of Agarose for Nucleic Acid Identification RNA of LDNVs was isolated and purified with the HiPure exosome RNA kit (Guangdong, China). The nucleic acid identification was performed during 2% agarose electrophoresis. The RNA bands were clearly visualized and documented using an automatic chemiluminescence fluorescence image analysis system. Coomassie Brilliant Blue Staining for Protein Identification The protein of LDNVs was extracted with RIPA lysate and subjected to electrophoresis with 4%–20% GenScript SDS‐PAGE gels (Jiangsu, China) after denaturation. Subsequently, the SDS‐PAGE gel was subjected to Vazyme Coomassie blue (Jiangsu, China) staining for 40 min and then rinsed with distilled water two times. The protein in the gel was analyzed using an automatic chemiluminescence fluorescence image analysis system. The protein concentration of LDNVs was detected with a Beyotime commercial enhanced BCA kit (Shanghai, China). Thin‐Layer Chromatography for Lipid Identification LDNVs solution was mixed with chloroform and methanol in an 8:1:1 ratio and centrifuged at 10 000 g for 10 min to extract the total lipids from LDNVs. The bottom layer was collected and dried. Subsequently, it was resuspended in chloroform, and lipids were detected by thin‐layer chromatography (TLC). Lipid Composition of LDNVs Lipid of LDNVs was extracted by chloroform and methanol (2:1) with 0.01% butylated hydroxytoluene. The sample was centrifuged (12 000 rpm, 10 min, 4°C) after ultrasound in ice. After concentration in a vacuum, sample was dissolved in isopropanol and methanol (9:1) and detected through LC–MS. Hemolysis Test and Serum Stability The whole blood of the SD rat was collected in a conical flask with steel beads. The flask was shaken for 10 min to remove fibrinogen. The blood was resuspended with 0.9% saline and then centrifuged at 1500 rpm for 15 min. After discarding the supernatant, the erythrocyte sediment was resuspended and centrifuged four times again until the erythrocyte suspension was clarified. A positive control group (distilled water) and a negative control group (0.9% saline), as well as five LDNVs groups with concentrations of 0.2, 0.4, 0.6, 0.8, and 1.0 mg/mL, were set up. Further, a 2% erythrocyte suspension was added with the same volume of distilled water, PBS, and different concentrations of LDNVs, respectively. After incubation at 37°C for 2 h, samples were centrifuged at 1500 rpm for 15 min. The supernatant was taken to measure the optical density (OD) value at 540 nm. Lastly, the hemolysis rate was calculated using the formula: hemolysis rate = (OD sample test group—OD negative control group) / (OD positive control group—OD negative control group) × 100%. In serum stability, the size, zeta potential, and PDI of LDNVs were measured after incubation in 20% FBS at 37°C for 24 h. In Vivo Biodistribution of LDNVs For the in vivo biodistribution of LDNVs, LDNVs were first labeled with Umibio exosome fluorescent labeling dye (DIR) (Shanghai, China) by incubation at 37°C for 30 min. After the unlabeled DIR was removed, BALB/c male mice were intravenously administered with free DIR or DIR@LDNVs (0.8 mg/kg). Mice were euthanized after 24 h. The heart, lung, liver, spleen, and kidney tissues were harvested to track the distribution of LDNVs by ex vivo tissue imaging analysis. DIR fluorescent signals were determined and quantified using the IVIS Spectrum (Perkin–Elmer Instruments Co. Ltd., USA). Then, the single‐cell suspension of lung tissue was prepared in the dark and resuspended in PBS containing 0.1% BSA after red blood cell lysis, at a concentration of 1 × 106 cells/100 µL. Ly6G‐FITC and CD11b‐PE/Cyanine7 antibodies (BioLegend, California, USA) were added to label the neutrophils. The labeled cells were then washed with PBS containing 0.1% BSA and analyzed using a flow cytometer (NovoCyte Quanteon, Agilent, USA). Mean fluorescence intensity (MFI) of DIR in each neutrophil was calculated to evaluate the cell uptake ability of LDNVs in neutrophils. ALI Mouse Therapeutic Model Male BALB/c mice (8 weeks old) were purchased from the Zhuhai BesTest Bio‐Tech Co., Ltd. (specific pathogen‐free degree; certificate number: SCXK (yue) 2025‐0051). All experiments were performed under the Declaration of Helsinki (Ethical Number: 20250926001). Eight‐week‐old male BALB/c mice were randomly divided into a control group, an ALI group, a dexamethasone (DXM) group, a Lonicera japonica extract (LJE) group, a LDNVs (p.o.) group, and a LDNVs (i.v.) group, with an average of eight animals in each group. The mice were housed under a 12 h light/dark cycle at a relative temperature of 25°C ± 1°C and a relative humidity of 50% ± 5% and were allowed to freely access food and water. After 7 days of acclimatization, except for the control group, mice in other groups were given LPS intratracheally at a dose of 7 mg/kg on day 0 to establish the ALI model. Then, mice of different groups received different treatments according to corresponding figure. The dose of LDNVs is calculated based on total protein mass (BCA assay). Body weights and body temperatures were measured at 0, 1, 12, 24, and 36 h. Blood, lung, bronchoalveolar lavage fluid (BALF), heart, liver, spleen, and kidney were collected from the mice after anesthesia and execution at 36 h. The BALF was washed with PBS and harvested with a syringe. The protein concentration of BALF was detected with a Beyotime commercial enhanced BCA kit (Shanghai, China). For pathological evaluation, the right upper lung lobe, heart, liver, spleen, and kidney were fixed in 4% paraformaldehyde, and the remaining tissues were cryopreserved for further examination. Open Field Test After 12 h of model establishment, the mice were placed individually in a closed and opaque arena (30 cm × 30 cm × 30 cm width, length, and height), and the exploratory behavior of mice was video‐recorded for 5 min. No prior training sessions were conducted before the test. The remaining mouse feces and urine in the activity zone were cleaned with ethanol to reduce the impact of residual signals left by the previous mouse on the subsequent experimental mouse. The fully automated social behavior recognition and analysis system (Noldus (Beijing) Information Technology Co. Ltd.) recorded behavioral parameters, including total distance moved (cm), locomotion time (s), and immobility time (s). Measurement of Lung Vessel and Epithelial Permeability In Vivo With Evans Blue Solution Prepare 0.5% Evans Blue staining solution (Aladdin, Shanghai, China). After 35 h of model establishment, 200 µL of the dye was injected into the tail vein of each mouse. Mice were placed on a heating pad and waited 1 h. Cardiac perfusion of mice was performed with PBS after anesthesia, and the target lung tissue was collected for OCT embedding. Following sectioning, the sections were stained with DAPI. Finally, image and photograph fluorescence‐stained lung tissue sections using an OLYMPUS microscope, and then measure the MFI of the sections. Histopathological Examination Tissues from the lung, heart, liver, spleen, and kidney were fixed with 4% paraformaldehyde and dehydrated. Samples were embedded in paraffin and hematoxylin and eosin (H&E) stained after sectioning. Sections were scanned by a panoramic scanning electron microscope to view the images. The severity of lung injury was rated on a scale from 0 to 4 in terms of four items: alveolar congestion, hemorrhage, leukocyte infiltration, or neutrophil aggregation in the airspace or blood vessel walls, and edema, and each item was summed to give a total score [19]. Inflammatory Antibody Array Mouse inflammatory cytokine array assays were performed using the Mouse Inflammation Antibody Array C1 (RayBiotech, Atlanta, USA) according to the manufacturer's instructions to profile cytokine expression in serum and BALF. The signals were captured by the L00797C1 chemiluminescence imaging system (AmobioBiotech Co., Ltd., China). Data were analyzed by comparing the signal intensities of spots to a reference standard. Flow Cytometry of BALF and Lung Tissue The single‐cell suspension of BALF and lung tissue was prepared and resuspended in PBS containing 0.1% BSA after red blood cell lysis at a concentration of 1 × 106 cells/100 µL. The remaining steps were consistent with the above processing. Immunofluorescence Staining The paraffin sections of lung tissue were baked and blocked. The sections were incubated with S100A8 (Proteintech, Hubei, China), alpha smooth muscle actin (SMA) (Proteintech, Hubei, China), and Laminin (Immunoway, Jiangsu, China); and citrullinated histone H3 (Cit‐H3) (Abcam, Cambridge, UK) and myeloperoxidase (MPO) (Proteintech, Hubei, China); LC3 (Proteintech, Hubei, China) and Ly6G (Immunoway, Jiangsu, China) primary antibodies overnight at 4°C, respectively. The secondary antibody incubation was performed with the triple‐fluorescence immunohistochemical mouse/rabbit kit, and the staining method was according to the manufacturer's instructions (Immunoway, Jiangsu, China). Then, sections were followed by DAPI staining. Finally, fluorescently stained lung sections were imaged and photographed using ZEISS and OLYMPUS microscopes. Western Blotting Frozen lung tissues were taken and subjected to protein extraction, quantification, SDS‐PAGE electrophoresis, transmembrane, closure, and incubation with anti‐p62 (Immunoway, Jiangsu, China), anti‐LC3B (Immunoway, Jiangsu, China), and anti‐GAPDH (Affinity, Jiangsu, China). The membranes were incubated with the respective secondary antibodies at room temperature. The signals were captured by the L00797C1 chemiluminescence imaging system (AmobioBiotech Co., Ltd., China). Protein semi‐quantitative analysis was performed by ImageJ software for greyscale scanning. Observation of Lung Tissue by Transmission Electron Microscope The left lung lobe was cut into small pieces and placed into pre‐cooled electron microscopy fixative. After fixation and room‐temperature dehydration, the samples were subjected to infiltration and embedding. The embedding models with resin and samples were moved into a 60°C oven to polymerize for 48 h. Semi‐thin sections of 1.5 µm were prepared and stained with toluidine blue for localization under light microscopy. The resin blocks were then sectioned into ultra‐thin slices (60–80 nm) using a microtome and collected on a 150‐mesh cuboidine membrane copper grid. The copper grid was stained for 8 min in a 2% uranyl acetate saturated alcohol solution under light protection. After washing, it was re‐stained for 8 min in a 2.6% lead citrate solution to avoid CO2 contamination. The grid was rinsed again and slightly dried with filter paper. The copper grid was dried at room temperature overnight and observed under TEM for image acquisition and analysis. Bio‐Safety of LDNVs in ALI Mice The heart, liver, spleen, and kidney were weighed. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CRE), and blood urea nitrogen (BUN) were detected with the Nanjing Jiancheng commercial kits (Jiangsu, China). Validation of Drug Efficacy Eight‐week‐old male BALB/c mice were randomly divided into a control group, an LPS group, an LPS+phorbol myristate acetate (PMA) group, and an LDNVs (i.v.) group, with an average of six animals in each group. The mice were housed under a 12 h light/dark cycle at a relative temperature of 25°C ± 1°C and a relative humidity of 50% ± 5% and were allowed to freely access food and water. Except for the standard control group, mice in the LPS group were given LPS intratracheally at a dose of 7 mg/kg on day 0, and mice in other groups were given LPS at a dose of 7 mg/kg and PMA at a dose of 0.4 mg/kg intratracheally on day 0. Then, the mice received different treatments according to corresponding figure. Their body weights and body temperatures were measured at 0, 1 min, 12, 24, and 36 h. After 12 h of model establishment, the mice were subjected to the open field test. Blood and lungs were collected from the mice after anesthesia and execution at 36 h. For pathological evaluation, the right upper lung lobes were fixed in 4% paraformaldehyde, and the remaining tissues were cryopreserved for further examination. Data Statistics StatView 5.0.1 was used for all the statistical computations. If the data fit a normal distribution, a homogeneity test of variance was performed. If the data fit the homogeneity of variance, a one‐way analysis of variance was performed for comparisons among multiple groups. p < 0.05 was regarded as statistically significant. All results are expressed as means ± SEM. Results Preparation and Characterization of LDNVs The liquid obtained by grinding and filtering a 1:5 mixture of Lonicera japonica and PBS was purified by sequential gradient centrifugation (2000 g centrifugation for 20 min, 3000 g centrifugation for 30 min, and 12 000 g centrifugation for 60 min) to remove cellular debris. The supernatant was collected and ultra‐centrifuged at 150 000 g for 90 min to remove the polysaccharide gel (Figure S1A,B). The centrifuged precipitate was resuspended in PBS. The solution was sequentially filtered through three filter membranes of 1.0, 0.45, and 0.22 µm in pore size and ultrafiltered by ultrafiltration tubes to collect the purified LDNVs (Figure 1A). The Flow NanoAnalyzer determined the size of the LDNVs was approximately 72.03±3.23 nm (Figure 1B). Dynamic light scattering analysis showed that LDNVs displayed PDI around 0.19 ± 0.01, which indicates good dispersion (Figure 1C). The zeta potentials of LDNVs were −13.91 ± 1.62 mV (Figure 1D), and the protein concentration was 15.27 ± 1.58 mg/mL (Figure 1E). TEM revealed that LDNVs displayed a saucer‐like morphology (Figure 1F). RNA extracted from LDNVs was primarily 1500 bp (Figure S1C). SDS‐PAGE analysis indicated that the molecular weight of the proteins in LDNVs ranged from 55 to 70 kDa (Figure S1D). We investigated the lipids of LDNVs by TLC and found that LDNVs contained different forms of lipids (Figure S1E). Additionally, the species and composition of LDNVs were performed by LC‐MS analysis (Figure S2). Ceramide, monoglyceride, diacylglycerol, triglyceride and cardiolipin were the main components of LDNVs (Figure S2). Characterization and bio‐distribution of LDNVs. Visualization of purified LDNVs (A). Size distribution (B), PDI (C), ζ potential (D), protein concentration (E), and morphological TEM images (F) of LDNVs. Images (G) and hemolysis rate (H) of LDNVs. The ex vivo major organs imaging (I) and MFI of DiR in each organ (J). Distribution of dot spots (K) of neutrophils and the MFI of DiR per neutrophil in lungs (L‐M). Values are means ± SEM, n = 3 per group. *p < 0.05, versus DiR@LDNVs group. The evaluation of hemocompatibility in LDNVs (0.2–1.0 mg/mL) with rat erythrocytes displayed that the color of LDNVs was similar to the negative group, and their hemolysis ratios were less than 5% (Figure 1G,H). The size, PDI, and zeta potential of LDNVs did not change significantly within 24 h in serum (Figure S3A–C). The results indicated that LDNVs possess benign injection safety. DiR‐labeled LDNVs were prepared to trace their biodistribution using IVIS Spectrum. We observed that predominant DiR@LDNVs fluorescent signals were higher in the lung, liver and kidney than those of free DiR (Figure 1I,J). Although LDNVs also enhanced the drug enrichment in liver and kidney. LDNVs can still partially enhance the pulmonary drug delivery. In addition, the MFI of DiR per neutrophil in lung tissue of the DiR@LDNVs group was significantly higher than in the free DiR group (Figure 1K–M), indicating that LDNVs could target neutrophils in lung tissue. Intravenous Delivery Enhances the Protective Effects of LDNVs Against LPS‐Induced ALI ALI mice were established via airway instillation of LPS and then treated with p.o. or i.v. drugs, respectively. After 36 h, lung tissues were harvested for analysis (Figure 2A). LDNVs (i.v.) significantly delayed LPS‐induced weight loss and were more effective than those treated with p.o. LDNVs, LJE, and DXM (Figure 2B). In the open field test, which evaluated exploratory behavior, the ALI group reduced total distance moved obviously (Figure 2C,G,H). Compared with the control group, the ALI group had a significantly shorter locomotion time and longer immobility time. These changes were reversed by treating with LDNVs (i.v.) remarkably (Figure 2D,E). The result showed that the physical activity of ALI mice has been improved significantly by treating with LDNVs (i.v.). In addition, LDNVs (i.v.) decreased the lung index in ALI mice, indicating relief of lung edema more effectively than other drug groups (Figure 2F). Thermal imaging revealed a significant decrease in body temperature among the ALI group, reaching its lowest point 12 h post‐modeling (Figure 2I and Figure S4). LDNVs demonstrated a reduced rate of temperature decline (Figure 2I). Actual lung images indicated that the ALI group lungs are enlarged with evident ecchymosis, and the LDNVs (i.v.) group showed improved pulmonary edema and reduced the severity of ecchymosis compared to other drug groups (Figure 2M). H&E staining of lung sections further validated this result and assessed the degree of lung injury through histopathological grading. Inflammatory cell infiltration and structural distortion were more severe in the ALI group (Figure 2J,N and Figure S5A). There was also an abundance of erythrocytes in the pulmonary interstitium and exudation in the bronchial lumen. LDNVs (i.v.) effectively inhibited this phenomenon and were more effective than other drug groups (Figure 2J,N). The protein concentration of BALF significantly increased in the ALI group. Compared with other groups, the LDNVs (i.v.) group effectively reduced the total protein levels in BALF (Figure 2K). Representative fluorescence images of Evans blue demonstrated significant enhancement in the lung tissues of ALI mice, indicating impaired integrity of pulmonary vessels and epithelial barriers. Following intravenous injection of LDNVs, lung vessel and epithelial permeability were markedly reduced, with therapeutic efficacy significantly superior to that of the LJE‐treated group (Figure 2L,O). In summary, LDNVs (i.v.) could ameliorate LPS‐induced ALI. But the LDNVs (p.o.) lost most of therapeutic effects of LDNVs in ALI mice. Meanwhile, DXM and LJE show hardly effects in ALI mice. Effects of LDNVs in treating LPS‐induced ALI. Therapeutic schedule of LDNVs in treating ALI (A). Body weight changes (B), total distance moved (C), locomotion time (D), immobility (E) and lung index (F) of mice. Heat map (G) and motion trails (H) in an open field test. Body temperature changes of mice (I). Lung injury scores (J), total protein in BALF (K), the MFI of Evans blue per section (L), representative images of lungs (M) and H&E staining images of lungs (N) and fluorescence images of Evans blue (O) in lungs. Values are means ± SEM, n = 6–8 per group. *p < 0.05, **p < 0.01 versus ALI group. #p < 0.05, ##p < 0.01 versus LDNVs group. LDNVs Reduce Inflammatory Cytokines in ALI Mice Due to the therapeutic effect of LDNVs was impaired in LDNVs (p.o.) group, the following section primarily compared the therapeutic mechanisms of LJE and LDNVs (i.v.) to determine whether there are any differences. To evaluate the impact of LDNVs on inflammatory responses, a panel of inflammatory mediators was examined in serum and BALF. Compared with the control group, we found that some inflammatory cytokines were significantly elevated in the BALF of the ALI group. Among these inflammatory cytokines, IL‐2 (Figure 3A), IL‐3 (Figure 3B), IL‐4 (Figure 3C), IL‐6 (Figure 3D), IL‐9 (Figure 3E), TNF‐α (Figure 3G), TNFSF6 (Figure 3H), and TNFRSF1B (Figure 3I) are suppressed by LDNVs in BALF and are more effective than the LJE‐treated group. Thereby alleviating the inflammatory storm in the lungs to achieve the goal of treating ALI. Inflammatory chemokines G‐CSF (Figure 3J), CXCL1 (Figure 3K), CCL5 (Figure 3M), CX3CL1 (Figure 3N), CXCL9 (Figure 3O), MIP‐γ (Figure 3P), CXCL13 (Figure 3Q), CCL24 (Figure 3R), and LIX (Figure S6A) were significantly increased in the ALI group. These cytokines, as common chemotactic factors for neutrophils, participate in the formation and regulation of NETs, thereby influencing the inflammatory environment [20, 21, 22, 23, 24]. Notably, chemotactic factors for other immune cells like CCL11 (Figure S6B), CXCL12α (Figure S6C), MIP‐1 (Figure S6D), and I309 (Figure S6E) were also elevated in the ALI group. Compared to the LJE‐treated group, LDNVs more effectively reduced the expression of G‐CSF (Figure 3J), CXCL1 (Figure 3K), CXCL9 (Figure 3O), MIP‐γ (Figure 3P), CXCL13 (Figure 3Q), CCL24 (Figure 3R), LIX (Figure S6A), and MIP‐1 (Figure S6D) in BALF. The results suggest that LDNVs may inhibit NETs formation by modulating neutrophil lung chemotaxis, thereby achieving therapeutic effects. Effects of LDNVs on inflammatory cytokines. Protein expression of IL‐2 (A), IL‐3 (B), IL‐4 (C), IL‐6 (D), IL‐9 (E), IL‐12 p40/p70 (F), TNFα (G), TNFSF6 (H), TNFRFS1B (I), G‐CSF (J), CXCL1 (K), CCL3 (L), CCL5 (M), CX3CL1 (N), CXCL9 (O), MIP‐1γ (P), CXCL13 (Q), CCL24 (R). Values are means ± SEM, * p < 0.05, **p < 0.01 versus ALI group. #p < 0.05, ##p < 0.01 versus LDNVs group. LDNVs Treatment Alleviates LPS‐Induced ALI by Reducing Neutrophils and NETs Accumulation in Lung Tissue Flow cytometry showed a notable increase in the expression of neutrophils (CD11b+Ly6G+) in the lung and BALF after LPS stimulation (Figure 4A–C). Following intervention with LDNVs (i.v.), the accumulation of neutrophils was inhibited (Figure 4A–C). Meanwhile, neutrophils were stained by S100A8 and laminin in immunofluorescence imaging. Representative immunofluorescence images demonstrated upregulation of neutrophil expression in lung tissue of ALI mice (Figure 4D,E). Treatment with LDNVs (i.v.) decreased the neutrophils in the lung, demonstrating superior therapeutic efficacy compared to the LJE‐treated group (Figure 4D,E). It was found that LPS‐induced ALI led to large pulmonary neutrophil clusters and severe inflammation. While LDNVs (i.v.) could effectively reduce neutrophil levels much more than the LJE‐treated group. Effects of LDNVs in NETs. Distribution of dot spots (A) of neutrophils and average of neutrophils in BALF (B) and lungs (C). Images (D) and counts (E) of pulmonary immunofluorescent staining of neutrophils. Images (F) and counts (G) of pulmonary immunofluorescent staining of NETs. Values are means ± SEM, n = 5–6 per group. *p < 0.05, **p < 0.01 versus ALI group. #p < 0.05, ##p < 0.01 versus LDNVs group. MPO and Cit‐H3, as NET‐associated markers, participate in NETs formation [25]. NETs formation was up‐regulated in the lung tissue of ALI mice, which was confirmed by immunofluorescence staining (Figure 4F,G). These results collectively confirmed that excessive infiltration of neutrophils and NETs was involved in the pathogenesis of ALI. Notably, intravenous administration of LDNVs reduced lung pathology associated with NETs accumulation. Treatment with LDNVs (i.v.) decreased the NETs, demonstrating superior therapeutic efficacy compared to the LJE‐treated group (Figure 4F,G). In conclusion, these results suggest that LDNVs may alleviate the pathological process of ALI by inhibiting the excessive infiltration of neutrophils and NETosis, demonstrating superior therapeutic efficacy compared to the LJE‐treated group. LDNVs Inhibit Autophagy Flux in Neutrophils of ALI Mice Excessive activation of autophagy can lead to lysosomal damage and NETosis, so inhibiting the autophagic flux can promote lysosomal stability and reduce NETs production [26, 27]. Subsequently, we analyzed the impact of LDNVs (i.v.) treatment on autophagy activation in lung tissue. In ALI model mice, LC3B II was enhanced with the depression of LC3B I/LC3B II and p62 (Figure 5A–F). Indeed, LC3B II was depressed and p62 expression was significantly enhanced by LDNVs (i.v.) treatment (Figure 5A–F). In addition, the pharmacological effect of Lonicera japonica extract was limited (Figure 5A–F). The immunofluorescence results demonstrated that the nuclear translocation of LC3 in neutrophils significantly increased under LPS stimulation compared with the control group (Figure 5G,H). Following LDNVs (i.v.) intervention, the nuclear translocation of autophagy marker LC3 [28] in neutrophils (Ly6G+) was significantly reduced, indicating a decreasing cellular damage (Figure 5G,H). The LJE treatment group has little therapeutic effect on this autophagy process (Figure 5G,H). The pulmonary‐damaged lysosomes were significantly increased in ALI mice compared with the control group. In ALI mice, lysosomes exhibited swelling, vacuolization, and reduced electron density, with discontinuous or ruptured limiting membranes. Some lysosomes displayed multilamellar whorled structures indicative of lysosomal stress or impaired degradation. Treatment with LDNVs (i.v.) decreased the number of damaged lysosomes in the lung, demonstrating superior therapeutic efficacy compared to the LJE‐treated group (Figure 5I,J). Therefore, LDNVs exert protective effects against LPS‐induced ALI in mice. These effects may be achieved by reducing autophagic flux and promoting the stability of lysosomes in neutrophils. Effects of LDNVs on autophagy and bio‐safety. Protein bands of LC3B I, LC3B II (A), p62 (B) and average level of LC3B I (C), LC3B II (D), LC3B I/II (E) and p62 (F). Images (G) and counts (H) of LC3 nuclear translocation in neutrophils. TEM images of lysosomes (I) and average numbers of damaged lysosomes per field (J) in lungs. Values are means ± SEM, n = 4–5 per group. *p < 0.05, **p < 0.01 versus ALI group. #p < 0.05, ##p < 0.01 versus LDNVs group. Bio‐Safety of LDNVs in ALI Mice To evaluate the biocompatibility of LDNVs in vivo, organs such as the heart, liver, spleen, and kidney were collected from each experimental group for weight and H&E staining. The results indicated no significant pathological alterations in the morphology of organs in each group (Figure S7A). There were no significant differences in the weights of organs in each group, except for the DXM group, demonstrating benign biosafety of LDNVs (Figure S7B–E). The serum levels of ALT, AST, BUN, and CRE in all drug groups showed no significant differences compared with the model group, except for the DXM group, indicating that LDNVs did not cause significant hepatic or renal injury (Figure S7F–I). PMA Blocks the Therapeutic Effects of LDNVs in ALI To further validate the effect of LDNVs in ALI and NETs, we used a pleiotropic neutrophils and NETs activator, PMA. ALI mice were established via airway instillation of LPS and PMA and then treated with LDNVs (i.v.). After 36 h, lung functions were tested, and tissues were harvested for analysis similarly (Figure 6A). The LPS+PMA group exhibited a significant decrease in body weight, with a greater reduction than that observed in mice with LPS‐induced ALI. No significant differences were observed in the LDNVs group (Figure 6B). In the open field test, the LPS+PMA group obviously reduced total distance moved (Figure 6C,G,H). At the same time, the LPS+PMA group had a significantly shorter locomotion time and longer immobility time. In contrast, LDNVs had no significant therapeutic effect (Figure 6D,E). Similarly, the LPS+PMA group increased the lung index in ALI mice obviously, and LDNVs had no significant effect (Figure 6F). BALF results show the LPS+PMA group appears red, indicating significant congestion in the lungs (Figure 6I). Thermal imaging revealed the LPS+PMA group's body temperature plummets at 1 h post‐modeling, reaching its lowest point 12 h post‐modeling. After 36 h, the body temperature remained lower than that of the LPS group and below normal levels (Figure 6J,K). Actual lung images indicated that the LPS+PMA group lungs were enlarged with evident ecchymosis, and the severity was greater than that in the LPS group (Figure 6L). H&E staining of lung sections further validated this result. Inflammatory cell infiltration and structural distortion were more severe in the LPS+PMA group. The therapeutic effect of LDNVs was not significant (Figure 6M,N and Figure S5B). The results indicated that the therapeutic effect of LDNVs was blocked by a pleiotropic neutrophils and NETs activator, suggesting that its efficacy may partially depend on inhibiting NETs. Effects of NETs agonist (PMA) in LDNVs treating ALI. Experimental schedule of PMA and LDNVs in treating ALI (A). Body weight changes (B), total distance moved (C), locomotion time (D), immobility (E), and lung index (F) of mice. Heat map (G), motion trails (H) in the open field test, and hemolysis images of BALF (I). Body temperature changes (J) and thermal imaging (K) of mice. Images of lungs (L), lung injury scores (M), and pulmonary H&E staining images (N) of mice. Values are means ± SEM, n = 4–6 per group. *p < 0.05, **p < 0.01 versus ALI group. #p < 0.05, ##p < 0.01 versus LDNVs group. PMA Neutralizes the Effects of LDNVs in NETs To understand the effects of LDNVs in NETs with PMA, we used flow cytometry and immunofluorescence imaging to assess neutrophil activity in vivo. Flow cytometry analysis of lung tissue revealed a significantly higher proportion of neutrophil population (CD11b+ Ly6G+) in the LPS group and LPS+PMA group compared with the control group (Figure 7A,B). There was no significant difference observed between the LPS+PMA and LDNVs (i.v.) groups (Figure 7A,B). The immunofluorescence results showed that the number of neutrophils in the lungs of LPS‐induced mice was increased. After intra‐tracheal LPS and PMA instillation, we observed an increase in the number of large pulmonary neutrophil clusters in the LPS+PMA and LDNVs (i.v.) groups (Figure 7C,D). Immunofluorescence staining targeting MPO and Cit‐H3 was utilized to specifically detect NETs within lung tissues. Immunofluorescence images demonstrated that LPS‐induced mice showed significantly increased NETs in the lungs (Figure 7E,F). After endotracheal perfusion of LPS and PMA, NETs in the LPS+PMA group accumulated extensively in the lungs (Figure 7E,F). Notably, LDNVs (i.v.) following LPS and PMA endotracheal perfusion did not reduce neutrophil and NETs accumulation (Figure 7E,F). The therapeutic effect of LDNVs on neutrophil extracellular trap formation was neutralized by PMA. Effects of LDNVs in NETs with PMA. Distribution of dot spots (A) of neutrophils and average neutrophils in lungs (B). Images (C) and counts (D) of pulmonary immunofluorescent staining of neutrophils. Images (E) and counts (F) of pulmonary immunofluorescent staining of NETs. Values are means ± SEM, n = 4–5 per group. *p < 0.05, **p < 0.01 versus ALI group. #p < 0.05, ##p < 0.01 versus LDNVs group. Discussion ALI is acute progressive dyspnea with persistent hypoxemia, caused by various pulmonary factors such as SARS‐CoV‐2 and extrapulmonary factors (non‐cardiogenic) [1, 29]. Severely, ALI may progress to acute respiratory distress syndrome (ARDS) [30]. Globally, the mortality rate associated with ALI/ARDS ranges from 30% to 40% annually [31]. Furthermore, limited drugs have been developed to effectively reduce the mortality rate of ALI [32]. Traditional drugs have limited efficacy because of their lack of targeting ability, and their active ingredients are difficult to concentrate on the lung lesions, which may cause side effects due to systemic diffusion [33]. Employing advanced nanocarrier systems significantly enhances drug delivery efficiency to the lungs and avoids potential side effects in non‐target tissues [34]. PDNVs are nanovesicle‐type microstructures of phospholipid bilayers embedded with therapeutic components, with benign biocompatibility and low toxicity [15, 35], which make them a natural nano‐drug delivery system [36, 37, 38]. In this study, we purified and characterized the LDNVs. It was found that LDNVs had a nanoscale size and a vesicle‐like structure, abundantly containing RNA, lipids, and a variety of proteins with various molecular weights. To indicate that LDNVs possess lung‐targeting capability, we traced the biodistribution of DiR‐labeled LDNVs. Although the LDNVs also increased the enrichment of DiR in liver and kidney. The results revealed that the fluorescent signals of DiR@LDNVs were predominantly stronger in the neutrophils of lung tissue compared with those of free DiR. The lung, as the main organ of gas exchange, has an extensive surface area and a dense vascular network, which provides a natural and optimal target for nanomedicine delivery [39]. In the ALI condition, the integrity of the pulmonary vascular barrier was impaired for evans blue permeation, which also facilitated the direct infiltration of LDNVs into pulmonary lesions. We suggested that nanovesicle size directly influences its hemodynamic behavior in circulation, including its ability to evade reticuloendothelial system clearance and its efficiency in penetrating vascular walls to reach target tissues, thereby achieving passive targeting [40]. The size of LDNVs was 72.03±3.23 nm, which was smaller than the range of the clearance of alveolar macrophages to nanoparticles but larger than the range of easy transfer out of the lung [41]. These findings highlighted LDNVs as a potential lung‐targeting therapeutic platform for ALI treatment. Subsequently, the toxicological experiment results showed that LDNVs at all tested concentrations exhibited low hemolytic activity and no toxic effects on animals. H&E staining results revealed no significant pathological alterations in the morphological structure of the heart, liver, spleen, or kidney across all experimental groups. The stability of LDNVs in serum remained stable for 24 h. These findings indicated that LDNVs possess benign biosafety profiles and could be used for intravenous administration. First, we induced an ALI mouse model by LPS airway instillation and investigated the differences between LDNVs and other drugs in treating ALI mice. The results showed that LDNVs (i.v.) could significantly delay weight loss and temperature decline in ALI mice, improve physical activity, and effectively inhibit the severe lung damage. Notably, the previous study has shown that the efficacy of glucocorticoids, traditional immunosuppressive agents, remains a subject of considerable controversy within the clinical management discourse in enhancing survival rates among patients with clinical acute lung injury [42, 43]. The result indicated that LDNVs (i.v.) have potential therapeutic effects in LPS induced ALI mice. But the DXM displayed hardly therapeutic effects in ALI as previous research [57]. Meanwhile, the LJE almost failed to attenuate the ALI. Compared to LDNVs (i.v.), LDNVs (p.o.) lost most of therapeutic effects of LDNVs. We consider that this may be due to the degradation of nanovesicles by gastric acid in the stomach, resulting in the loss of LDNVs enrichment on lung. However, considering the significant difference in bioavailability between p.o. and i.v. administration, the significance of this general comparison is very limited. We further investigated the therapeutic mechanisms of LDNVs (i.v.), which exert protective effects against pulmonary diseases. This study employed protein chip technology to analyze changes in chemokines in LPS‐induced ALI mice following LDNVs intervention. G‐CSF is the most essential growth factor for the production of granulocytes and their immediate precursors [20]. A study indicates that elevated levels of circulatory G‐CSF promote NETs formation [44]. CXCL1 produced by endothelial cells provides directional cues for neutrophil migration and facilitates their passage through the complex structure of the venous wall into inflamed tissues [20]. Knocking out CD276 in epithelial cells significantly downregulated CXCL1 expression, thereby inhibiting NETs formation through the CXCL1‐CXCR2 signaling axis [45]. As an inflammatory chemokine, CCL3 enables neutrophils to migrate along its concentration gradient in inflammatory environments [46]. Upregulating CCL3+ macrophage expression and downregulating S100A9+ neutrophil activity can inhibit NETs formation and promote angiogenesis [47]. LIX maintains a close regulatory relationship with neutrophils, primarily through inducing neutrophil migration via specific receptor binding and facilitating neutrophil activation to promote their engagement in inflammatory responses [20]. Existing research indicates that chemokines CCL5, CXCL1, CXCL9, MIP‐γ, CXCL13, and CCL24 chemotactically recruit neutrophils under specific conditions and indirectly participate in the regulation of NETs [20, 21, 22, 23, 48]. Our research findings implied that LDNVs might prevent excessive NETs formation by modulating neutrophil chemotaxis and activation within the lung tissue, thereby reducing tissue damage and exerting protective anti‐inflammatory effects. This mechanism contributed to the observed therapeutic outcomes, suggesting a potential therapeutic pathway for neutrophil‐driven inflammatory lung conditions. Further experimental results revealed that LDNVs could effectively alleviate the accumulation of neutrophils and NETosis in ALI mice. S100A8 and laminin can stimulate the chemotaxis and adhesion of neutrophils. We used them as immunofluorescence markers for neutrophils [49, 50]. Meanwhile, immunofluorescence analysis revealed abnormal laminin expression in the model group versus the control group, suggesting structural damage to the nuclear membrane. Concurrently, S100A8 upregulation pointed to enhanced neutrophil activation. Following intervention with LDNVs (i.v.), nuclear membrane structural integrity was restored, and the activation of neutrophils was inhibited [51]. MPO, a cytoplasmic functional marker, serves as a cytoplasmic localization reference and participates in NETs formation. Meanwhile, the NET‐associated marker Cit‐H3 indicates nuclear chromatin depolymerization and extracellular release, marking NETs formation [6]. Notably, as evidenced by co‐localization of MPO and CitH3, intravenous administration of LDNVs reduced lung pathology associated with NETs accumulation, highlighting the immunomodulatory role of LDNVs in inhibiting inflammatory responses and demonstrating superior therapeutic efficacy compared to the LJE‐treated group. However, the exact mechanism by which LDNVs regulate NETs formation to alleviate ALI and pulmonary inflammation remains unclear. The formation of NETs can be triggered by endogenous stimuli and microorganisms, resulting in the release of reticular structures composed of DNA scaffolds, histones, and granular proteins during neutrophil activation or apoptosis [6, 7]. Autophagy is a crucial cellular process through which organelles are degraded within lysosomes to protect cells and organisms from stressors [8]. The formation of NETs requires the involvement of autophagy, a specialized form of neutrophil programmed cell death termed NETosis [52, 53]. LC3 is the homologue of the yeast protein on autophagosomes, and its lipidated form LC3B II has been demonstrated to serve as a marker for mammalian autophagosomes [54]. P62, as a key adaptor protein, binds to degraded substances while interacting with the LC3 protein on autophagosomes. This enables the selective degradation of damaged organelles and other materials through the autophagy pathway, making it a classic marker for assessing autophagy activity [55]. The immunofluorescence results of LC3 demonstrated that the nuclear translocation of LC3 in neutrophils significantly increased under LPS stimulation, indicating the disruption of lysosomal membrane stability and the compromise of cellular structure. The TEM results revealed abundant damaged lysosomes in the lungs of the ALI group. LDNVs (i.v.) could have inhibitory effects on the autophagy flux in neutrophils of ALI mice, manifested as a reduction in the number of damaged lysosomes and decreased expression of LC3B II. This suggests a potential mechanism involving inhibition of LC3 nuclear transport and autophagy flux within neutrophils. In contrast, the LJE‐treated group showed minimal therapeutic impact on this autophagy process. This suggested that LDNVs may reduce NETs production by suppressing autophagy flux, thereby achieving therapeutic effects. Furthermore, we conducted an in vivo validation experiment of NETs to further verify their possible mechanism. PMA, an inducer of NETs, can stimulate neutrophils to release NETs [6, 56]. The results indicated that the LPS+PMA group exhibited more pronounced weight loss, severe lung injury, obvious pulmonary hemolysis, and locomotor activity decrease compared to the LPS‐only group. Intravenous administration of LDNVs, however, failed to significantly improve any of these indicators. The intra‐tracheal administration of LPS and PMA promoted the recruitment and aggregation of neutrophils and NETs in the lung tissue of both the LPS+PMA and the LDNVs (i.v.) groups. Although the PMA is also regarded as a pleiotropic activator in granulocytes. But considering the effects of PMA in NETs and LDNVs fail to demonstrate the therapeutic effects in NETs with PMA, we suggest the therapeutic effects of LDNVs in ALI are dependent on NETs partially. In addition, two mice in the LPS+PMA group succumbed during the observation period, potentially attributable to exacerbated inflammatory responses. Conversely, no mortality was observed in the LDNVs (i.v.) group. This indicates that although PMA largely neutralized the therapeutic efficacy of this treatment group, a small amount of therapeutic potential was retained. Overall, these in vivo results support our conception that the LDNVs significantly attenuate LPS‐induced ALI by effectively inhibiting the formation of NETs. These protective effects may be associated with LDNVs suppressing the autophagic flux, thereby modulating cellular processes that contribute to inflammatory damage. Author Contributions S.X., X.L., and J.L. designed the research protocol. X.L., J.L., Y.Z., and X.Z. performed the experimental research. S.X., X.L., and J.L. analyzed the data. X.L. and J.L. performed the formal analysis. X.L., H.S., J.L. provided the methodology and technical support. S.X., X.L., and Y.Z. wrote the manuscript. S.X., H.C., Z.D., and X.L. revised the manuscript. S.X., Z.D., and X.L. performed the project administration. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File: adhm71470‐sup‐0001‐SuppMat.doc.